Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06816992 · ClinicalTrials.gov registry record · Phase 1

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

A Phase 1 study of Solid Tumors and NSCLC, sponsored by ORIC Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
76
Enrollment target
4
Study locations

NCT06816992 is a Phase 1 study of Solid Tumors and NSCLC that is actively recruiting participants, run by ORIC Pharmaceuticals. The registered enrollment target is 76 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (73% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06816992, a Phase 1 study of Solid Tumors and NSCLC, is actively recruiting participants, sponsored by ORIC Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
76 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Conditions Studied

Solid Tumors NSCLC EGFR Exon 20 Insertion Mutations EGFR-mutated NSCLC

Interventions

  • DRUG ORIC-114 Dose 1 + amivantamab
  • DRUG ORIC-114 Dose 2 + amivantamab
  • DRUG ORIC-114 Dose 3 + amivantamab

Study Locations (4)

New York

  • NYU Langone Health - New York

Virginia

  • Virginia Cancer Specialists - Fairfax

Victoria

  • Peter MacCallum Cancer Centre - Melbourne

Ontario

  • The Princess Margaret Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2025-02-27
Est. Completion 2027-05
Phase Phase 1

Sponsor

ORIC Pharmaceuticals

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06816992

The ClinicalTrials.gov registry entry for NCT06816992 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (73% lower). The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which ORIC-114 Dose 1 + amivantamab is the first listed.

NCT06816992 reports 4 study locations spanning 4 distinct geographic areas - top geographies include New York, Virginia, Victoria.

Frequently Asked Questions

What is clinical trial NCT06816992 about?

NCT06816992 is a clinical study titled "ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC". The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 2...

What is the current status of trial NCT06816992?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2025-02-27. Estimated completion is 2027-05.

What conditions does trial NCT06816992 study?

This clinical trial studies the following conditions: Solid Tumors, NSCLC, EGFR Exon 20 Insertion Mutations, EGFR-mutated NSCLC.

What interventions are being tested in trial NCT06816992?

The interventions under investigation include: ORIC-114 Dose 1 + amivantamab (DRUG), ORIC-114 Dose 2 + amivantamab (DRUG), ORIC-114 Dose 3 + amivantamab (DRUG).

Who is sponsoring clinical trial NCT06816992?

This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06816992 being conducted?

This trial has 4 study locations across New York, Virginia, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

NSCLC

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.